Retinoids in cutaneous T cell lymphomas.
Sixteen patients - 12 with cutaneous T cell lymphoma (CTCL), 1 with Sézary syndrome, 1 with actinic reticuloid, and 2 with parapsoriasis variegata - were treated with either a new, potent arotinoid alone or with combined etretinate (Tigason) and PUVA therapy (Re-PUVA). 92% of all patients showed a minor up to a distinct response of their skin lesions within 12.6 +/- 7.4 weeks. More than 50% of the skin lesions cleared in 67% of the patients. After discontinuation of the retinoid therapy, relapses occurred in all cases within 3-10 weeks. There was no difference between the therapeutic efficacy of arotinoid alone and the Re-PUVA regimen, but the latter was less toxic.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D015474:Isotretinoin; D008223:Lymphoma / Q000188:drug therapy* / Q000628:therapy; D011701:PUVA Therapy; D012176:Retinoids / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000628:therapy; D013601:T-Lymphocytes; D014212:Tretinoin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001565:Benzoates; D012176:Retinoids; D014212:Tretinoin; C034814:ethyl-p-((E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-1-propenyl)benzoic acid; D015474:Isotretinoin